Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Pan, Li-Na1 | Ma, Yun-Fang1 | Hu, Jia-An* | Xu, Zhi-Hong*
Affiliations: Department of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China
Correspondence: [*] Corresponding authors: Zhi-Hong Xu, Department of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University, 197 Ruijin Second Road, Huangpu District, 200025, Shanghai, China. Tel.: +86 13916707605; Fax: +86 21 54198967; E-mail: zhihxu@163.com. Jia-An Hu, Department of Geriatrics, Ruijin Hospital, Shanghai Jiaotong University, 197 Ruijin Second Road, Huangpu District, 200025, Shanghai, China. Tel.: +86 13601737014; Fax: +86 21 54198967; E-mail: hja10310@rjh.com.cn.
Note: [1] These authors contributed equally to this work as the co-first authors.
Abstract: Circular RNA (circRNA) has been shown to participate in various tumors, including lung cancer. In the present study, we explored the expression and functional relevance of hsa_circ_0003288 in human non-small cell lung cancer (NSCLC). We verified that hsa_circ_0003288 expression was upregulated in lung cancer tissues and cell lines. Overexpression of hsa_circ_0003288 dramatically promoted lung cancer cell proliferation, colony formation, inhibited apoptosis, and increased cell migration and invasion in vitro. Xenograft experiments showed that hsa_circ_0003288 overexpression accelerated tumor growth in vivo. Mechanistically, hsa_circ_0003288 negatively regulated miR-145 to exert the oncogenic role in lung cancer. Overexpression of miR-145 decreased cell proliferation, induced apoptosis, and suppressed migration and invasion in lung cancer. Additionally, miR-145 co-transfection abolished the oncogenic role of hsa_circ_0003288. Collectively, these findings identified a novel regulatory role of hsa_circ_0003288/miR-145 axis in the progression of NSCLC.
Keywords: Non-small cell lung cancer, hsa_circ_0003288, miR-145
DOI: 10.3233/CBM-203198
Journal: Cancer Biomarkers, vol. 35, no. 4, pp. 349-357, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl